Among patients with acute coronary syndrome in SORT OUT III (defined as patients with unstable angina or myocardial infarction), the incidence of MACE at 18 months was significantly reduced by 43% with CYPHER vs. ENDEAVOR (5.0% in the CYPHER Stent group vs. 8.7% in the Endeavor(R) Stent group; hazard ratio 1.78; 95% confidence intervals: 1.10-2.88). This difference was driven by a statistically significant reduction in TLR and TVR favoring the CYPHER stent. In the CYPHER Stent group the incidence of MACE was also significantly reduced by 60% compared to the ENDEAVOR Stent in patients with stable angina (4.2% in the CYPHER Stent group vs. 10.4% in the ENDEAVOR Stent group; hazard ratio 2.53, 95% confidence intervals: 1.60-4.02).

Finally, among the high-risk group treated for disease in multiple lesions in SORT OUT III, the incidence of MACE at 18 months was significantly reduced by 80% with CYPHER vs. ENDEAVOR (2.6% in the CYPHER Stent group vs. 13.2% in the Endeavor(R) Stent group; hazard ratio 5.29; 95% confidence intervals: 2.59-10.8). This difference was driven by statistically significant reductions in death, MI, and TVR favoring the CYPHER Stent. In the CYPHER Stent group the incidence of MACE was also significantly reduced by 35% compared to the ENDEAVOR Stent in patients treated for disease in one lesion (5.4% in the CYPHER Stent group vs. 8.3% in the ENDEAVOR Stent group; hazard ratio 1.55, 95% confidence intervals: 1.06-2.27).

"The SORT OUT III subgroup analyses further support significant safety and efficacy differences between the CYPHER(R) Stent and the Endeavor(R) Stent," said Campbell Rogers, M.D., Chief Scientific Officer and Head, Global Research and Development, Cordis Corporation and concludes, "In these data sets, risks of adverse events are up to five-fold higher with the Endeavor(R) Stent than with the CYPHER(R) Stent in patients with other complications like diabetes that are described in these data."

SOURCE Cordis Corporation